한글목차

세계의 안티센스 올리고뉴클레오티드(ASO) 치료제 시장 규모는 2033년까지 14.5%의 CAGR로 성장할 것으로 예측되고 있습니다.

희귀질환 치료에 ASO 치료제 채택으로 시장 성장 견인

안티센스 올리고뉴클레오티드(ASO)의 희귀 유전성 질환 치료에 대한 적용은 이 치료 접근법이 얼마나 혁신적인지 보여주는 강력한 증거입니다. 희귀질환은 인구의 낮은 유병률로 인해 기존 의약품 개발에서 그다지 매력적이지 않았습니다. 그러나 ASO는 이러한 질환을 앓고 있는 사람들에게 희망의 빛이 되고 있으며, ASO R&D에 많은 관심과 투자가 이루어지고 있습니다.

기존의 의약품 개발 경로에서 희귀질환은 종종 큰 장벽에 직면합니다. 환자 수가 적기 때문에 대규모 임상시험을 진행하기 어렵고, 이러한 질환에 대한 의약품 개발의 재정적 타당성에도 문제가 있으며, ASO는 정확성과 적응성을 통해 이러한 문제를 해결할 수 있는 새로운 가능성을 열어주고 있습니다.

ASO는 희귀질환을 유발하는 특정 유전자 돌연변이 또는 이상을 표적으로 삼도록 조정할 수 있습니다. 이러한 개별화된 접근 방식은 단순히 증상을 관리하는 것이 아니라 증상의 근본 원인을 직접적으로 치료할 수 있는 치료법을 개발할 수 있게 합니다. 이는 희귀질환의 치료 환경을 변화시킬 수 있는 잠재력을 가지고 있으며, 지금까지 없었던 효과적인 질병 변형 치료의 가능성을 제공합니다.

세계의 안티센스 올리고뉴클레오티드(ASO) 치료제 시장을 조사했으며, 시장 개요, 시장 성장에 대한 각종 영향요인 분석, 시장 규모의 추이·예측, 각종 구분·지역/주요 국가별 내역, 경쟁 환경, 주요 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 리포트의 개요

제2장 주요 요약

제3장 시장 개요

• 주요 조사 결과
• 시장 역학
  • 시장 촉진요인
  • 시장 억제요인
  • 시장 기회
• COVID-19의 영향 분석
• Porter's Five Forces 분석
• PEST 분석

제4장 안티센스 올리고뉴클레오티드(ASO) 치료제 시장 분석 : 치료 용도별

• 주요 조사 결과
• 시장 매력 지수
• 시장 규모 추산·예측
• 신경학적 장애
• 유전성 질환
• 종양성 질환
• 심혈관질환
• 기타

제5장 안티센스 올리고뉴클레오티드(ASO) 치료제 시장 분석 : ASO 화학별

• 주요 조사 결과
• 시장 매력 지수
• 시장 규모 추산·예측
• DNA 기반
• RNA 기반
• Gapmer

제6장 안티센스 올리고뉴클레오티드(ASO) 치료제 시장 분석 : 투여 경로별

• 주요 조사 결과
• 시장 매력 지수
• 시장 규모 추산·예측
• 경폐투여
• 정맥주사
• 피내 주사
• 복강내 주사
• 국소 투여
• 기타

제7장 안티센스 올리고뉴클레오티드(ASO) 치료제 시장 분석 : 지역별

• 주요 조사 결과
• 시장 규모 추산·예측

제8장 북미의 안티센스 올리고뉴클레오티드(ASO) 치료제 시장 분석

제9장 유럽의 안티센스 올리고뉴클레오티드(ASO) 치료제 시장 분석

제10장 아시아태평양의 안티센스 올리고뉴클레오티드(ASO) 치료제 시장 분석

제11장 라틴아메리카의 안티센스 올리고뉴클레오티드(ASO) 치료제 시장 분석

제12장 중동 및 아프리카의 안티센스 올리고뉴클레오티드(ASO) 치료제 시장 분석

제13장 기업 개요

• 경쟁 구도
• 전략적 전망
• Biogen
• Bio-Path Holdings
• Ionis Pharmaceuticals, Inc.
• ProQR Therapeutics
• Sarepta Therapeutics
• Alnylam Pharmaceuticals, Inc.
• Arrowhead Pharmaceuticals, Inc.
• GSK plc
• Geron Corporation(Geron)
• Antisense Therapeutics Limited
• Sterna Biologicals
• Alector, Inc.
• Dicerna Pharmaceuticals, Inc.
• iCo Therapeutics Inc.
• Roche Holding AG

제14장 결론·제안

• Visiongain에 의한 결론
• 시장 참여 기업에 대한 제안

영문목차

The global Antisense Oligonucleotide (ASO) Therapeutics market is projected to grow at a CAGR of 14.5% by 2033.

“The Antisense Oligonucleotide (ASO) Therapeutics Market Report 2023-2033”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Adoption of ASO Therapeutics for the Treatment of Rare Diseases Driving Market Growth

The application of antisense oligonucleotides (ASOs) in the treatment of rare genetic disorders is a compelling testament to the transformative power of this therapeutic approach. Rare diseases, often referred to as orphan diseases, are characterized by their low prevalence in the population, making them less attractive for traditional drug development efforts. However, ASOs have emerged as a ray of hope for individuals afflicted by these conditions, driving considerable interest and investment in ASO research and development.

Traditional drug development pathways often face significant hurdles when it comes to rare diseases. The small patient populations make conducting large-scale clinical trials challenging, and the financial viability of developing drugs for such conditions can be questionable. ASOs, with their precision and adaptability, have opened up new possibilities for addressing these challenges.

ASOs can be tailored to target the specific genetic mutations or abnormalities responsible for rare diseases. This personalized approach allows for the development of therapies that directly address the underlying cause of the condition, rather than just managing symptoms. This has the potential to revolutionize the treatment landscape for rare diseases, offering the prospect of effective, disease-modifying treatments where none existed before.

Potential Immunogenicity Response in Some Patients Likely to Challenge Industry Growth

Immunogenicity poses a significant market restraint for the antisense oligonucleotide (ASO) Therapeutics Market. While ASOs hold immense promise in treating a range of diseases, the potential to provoke an immune response in some patients can lead to adverse effects and reduced treatment effectiveness. This immunogenic response may hinder the widespread adoption of ASO therapies and pose challenges in terms of patient safety and regulatory approvals. To mitigate this concern, extensive research and development efforts have been focused on chemical modifications and structural alterations to ASO molecules to reduce their immunogenicity.

What Questions Should You Ask before Buying a Market Research Report?

• How is the Antisense Oligonucleotide (ASO) Therapeutics market evolving?
• What is driving and restraining the Antisense Oligonucleotide (ASO) Therapeutics market?
• How will each Antisense Oligonucleotide (ASO) Therapeutics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each Antisense Oligonucleotide (ASO) Therapeutics submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading Antisense Oligonucleotide (ASO) Therapeutics markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the Antisense Oligonucleotide (ASO) Therapeutics projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of Antisense Oligonucleotide (ASO) Therapeutics projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the Antisense Oligonucleotide (ASO) Therapeutics market?
• Where is the Antisense Oligonucleotide (ASO) Therapeutics market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Antisense Oligonucleotide (ASO) Therapeutics market today, and over the next 10 years:

• Our 286-page report provides 107 tables and 151 charts/graphs exclusively to you
• The report highlights key lucrative areas in the industry so you can target them - NOW
• It contains in-depth analysis of global, regional and national sales and growth
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Antisense Oligonucleotide (ASO) Therapeutics market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares
• You will find original analyses, with business outlooks and developments
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Antisense Oligonucleotide (ASO) Therapeutics prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report:

Therapeutic Application

• Neurological Disorders
• Genetic Disorders
• Oncological Disorders
• Cardiovascular Diseases
• Others

ASO Chemistry

• DNA Based ASO
• RNA Based ASO
• Gapmer ASO

Route of Administration

• Pulmonary Delivery
• Intravenous Injections
• Intradermal Injections
• Intraperitoneal Injections
• Topical Delivery
• Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 24 leading national markets:

North America

• U.S
• Canada

Europe

• Germany
• France
• UK
• Italy
• Spain
• Russia
• Rest of Europe

Asia Pacific

• Japan
• China
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Argentina
• Colombia
• Rest of Latin America

MEA

• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Antisense Oligonucleotide (ASO) Therapeutics Market, 2023 to 2033, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth:

Overall world revenue for Antisense Oligonucleotide (ASO) Therapeutics Market, 2023 to 2033 in terms of value the market will surpass US$6,000.0 million in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the “Antisense Oligonucleotide (ASO) Therapeutics Market, 2023 to 2033 ” report help you?

In summary, our 280+ page report provides you with the following knowledge:

• Revenue forecasts to 2033 for Antisense Oligonucleotide (ASO) Therapeutics Market, 2023 to 2033 Market, with forecasts for therapeutic application, ASO chemistry, and route of administration, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2033 for five regional and 24 key national markets - See forecasts for the Antisense Oligonucleotide (ASO) Therapeutics Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market - including company profiles for 15 of the major companies involved in the Antisense Oligonucleotide (ASO) Therapeutics Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Table of Contents

1 Report Overview

• 1.1 Objectives of the Study
• 1.2 Introduction to Antisense Oligonucleotide (ASO) Therapeutics Market
• 1.3 What This Report Delivers
• 1.4 Why You Should Read This Report
• 1.5 Key Questions Answered by This Analytical Report
• 1.6 Who is This Report for?
• 1.7 Methodology
  • 1.7.1 Market Definitions
  • 1.7.2 Market Evaluation & Forecasting Methodology
  • 1.7.3 Data Validation
    • 1.7.3.1 Primary Research
    • 1.7.3.2 Secondary Research
• 1.8 Frequently Asked Questions (FAQs)
• 1.9 Associated Visiongain Reports
• 1.10 About Visiongain

2 Executive Summary

3 Market Overview

• 3.1 Key Findings
• 3.2 Market Dynamics
  • 3.2.1 Market Driving Factors
    • 3.2.1.1 Developments in the Field of Target Specific Precision Medicine Driving the ASO Therapeutics Market
    • 3.2.1.2 Adoption of ASO Therapeutics for the Treatment of Rare Diseases Driving the ASO Therapeutics Market
    • 3.2.1.3 Improved Delivery Systems Helps in Unlocking the Full Potential of ASOs, thereby Boosting the Market
  • 3.2.2 Market Restraining Factors
    • 3.2.2.1 Off-target Effects Might Act as a Significant Market Restraint in the Development and Adoption of ASO Therapeutics
    • 3.2.2.2 Potential Immunogenicity Response in Some Patients Might Restrain the ASO Therapeutics Market Growth
    • 3.2.2.3 High Cost of Treatment and Manufacturing of ASO Therapeutics Might Impact the Market Growth Negatively
  • 3.2.3 Market Opportunities
    • 3.2.3.1 Novel Approach to Cancer Therapy Might Offer a Promising Market Opportunity to ASO Therapeutics
    • 3.2.3.2 Pipeline Expansion Stands as a Significant Market Opportunity Within the Realm of ASO Therapeutics
    • 3.2.3.3 In the Field of ASO Therapeutics, the Availability of Regulatory Support is a Significant Market Potential
• 3.3 COVID-19 Impact Analysis
• 3.4 Porter's Five Forces Analysis
  • 3.4.1 Bargaining Power of Suppliers
  • 3.4.2 Bargaining Power of Buyers
  • 3.4.3 Competitive Rivalry
  • 3.4.4 Threat from Substitutes
  • 3.4.5 Threat of New Entrants
• 3.5 PEST Analysis

4 Antisense Oligonucleotide (ASO) Therapeutics Market Analysis by Therapeutic Application

• 4.1 Key Findings
• 4.2 Therapeutic Application Segment: Market Attractiveness Index
• 4.3 Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Therapeutic Application
• 4.4 Neurological Disorders
  • 4.4.1 Market Size by Region, 2023-2033 (US$ Million)
  • 4.4.2 Market Share by Region, 2023 & 2033 (%)
• 4.5 Genetic Disorders
  • 4.5.1 Market Size by Region, 2023-2033 (US$ Million)
  • 4.5.2 Market Share by Region, 2023 & 2033 (%)
• 4.6 Oncological Disorders
  • 4.6.1 Market Size by Region, 2023-2033 (US$ Million)
  • 4.6.2 Market Share by Region, 2023 & 2033 (%)
• 4.7 Cardiovascular Diseases
  • 4.7.1 Market Size by Region, 2023-2033 (US$ Million)
  • 4.7.2 Market Share by Region, 2023 & 2033 (%)
• 4.8 Others
  • 4.8.1 Market Size by Region, 2023-2033 (US$ Million)
  • 4.8.2 Market Share by Region, 2023 & 2033 (%)

5 Antisense Oligonucleotide (ASO) Therapeutics Market Analysis by ASO Chemistry

• 5.1 Key Findings
• 5.2 ASO Chemistry Segment: Market Attractiveness Index
• 5.3 Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by ASO Chemistry
• 5.4 DNA Based ASO
  • 5.4.1 Market Size by Region, 2023-2033 (US$ Million)
  • 5.4.2 Market Share by Region, 2023 & 2033 (%)
• 5.5 RNA Based ASO
  • 5.5.1 Market Size by Region, 2023-2033 (US$ Million)
  • 5.5.2 Market Share by Region, 2023 & 2033 (%)
• 5.6 Gapmer ASO
  • 5.6.1 Market Size by Region, 2023-2033 (US$ Million)
  • 5.6.2 Market Share by Region, 2023 & 2033 (%)

6 Antisense Oligonucleotide (ASO) Therapeutics Market Analysis by Route of Administration

• 6.1 Key Findings
• 6.2 Route of Administration Segment: Market Attractiveness Index
• 6.3 Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Route of Administration
• 6.4 Pulmonary Delivery
  • 6.4.1 Market Size by Region, 2023-2033 (US$ Million)
  • 6.4.2 Market Share by Region, 2023 & 2033 (%)
• 6.5 Intravenous Injections
  • 6.5.1 Market Size by Region, 2023-2033 (US$ Million)
  • 6.5.2 Market Share by Region, 2023 & 2033 (%)
• 6.6 Intradermal Injections
  • 6.6.1 Market Size by Region, 2023-2033 (US$ Million)
  • 6.6.2 Market Share by Region, 2023 & 2033 (%)
• 6.7 Intraperitoneal Injections
  • 6.7.1 Market Size by Region, 2023-2033 (US$ Million)
  • 6.7.2 Market Share by Region, 2023 & 2033 (%)
• 6.8 Topical Delivery
  • 6.8.1 Market Size by Region, 2023-2033 (US$ Million)
  • 6.8.2 Market Share by Region, 2023 & 2033 (%)
• 6.9 Others
  • 6.9.1 Market Size by Region, 2023-2033 (US$ Million)
  • 6.9.2 Market Share by Region, 2023 & 2033 (%)

7 Antisense Oligonucleotide (ASO) Therapeutics Market Analysis by Region

• 7.1 Key Findings
• 7.2 Regional Market Size Estimation and Forecast

8 North America Antisense Oligonucleotide (ASO) Therapeutics Market Analysis

• 8.1 Key Findings
• 8.2 North America Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index
• 8.3 North America Antisense Oligonucleotide (ASO) Therapeutics Market .by Country, 2023, 2028 & 2033 (US$ Million)
• 8.4 North America Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Country
• 8.5 North America Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Therapeutic Application
• 8.6 North America Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by ASO Chemistry
• 8.7 North America Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Route of Administration
• 8.8 U.S. Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
• 8.9 Canada Antisense Oligonucleotide (ASO) Therapeutics Market Analysis

9 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Analysis

• 9.1 Key Findings
• 9.2 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index
• 9.3 Europe Antisense Oligonucleotide (ASO) Therapeutics Market by Country, 2023, 2028 & 2033 (US$ Million)
• 9.4 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Country
• 9.5 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Therapeutic Application
• 9.6 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by ASO Chemistry
• 9.7 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Route of Administration
• 9.8 Germany Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
• 9.9 France Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
• 9.10 UK Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
• 9.11 Italy Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
• 9.12 Spain Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
• 9.13 Russia Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
• 9.14 Rest of Europe Antisense Oligonucleotide (ASO) Therapeutics Market Analysis

10 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market analysis

• 10.1 Key Findings
• 10.2 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index
• 10.3 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market by Country, 2023, 2028 & 2033 (US$ Million)
• 10.4 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Country
• 10.5 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Therapeutic Application
• 10.6 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by ASO Chemistry
• 10.7 Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Route of Administration
• 10.8 Japan Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
• 10.9 China Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
• 10.10 India Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
• 10.11 Australia Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
• 10.12 South Korea Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
• 10.13 Singapore Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
• 10.14 Rest of Asia Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Analysis

11 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Analysis

• 11.1 Key Findings
• 11.2 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index
• 11.3 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market .by Country, 2023, 2028 & 2033 (US$ Million)
• 11.4 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Country
• 11.5 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Therapeutic Application
• 11.6 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by ASO Chemistry
• 11.7 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Route of Administration
• 11.8 Brazil Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
• 11.9 Mexico Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
• 11.10 Argentina Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
• 11.11 Colombia Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
• 11.12 Rest of Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Analysis

12 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Analysis

• 12.1 Key Findings
• 12.2 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Attractiveness Index
• 12.3 MEA Antisense Oligonucleotide (ASO) Therapeutics Market by Country, 2023, 2028 & 2033 (US$ Million)
• 12.4 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Country
• 12.5 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Therapeutic Application
• 12.6 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by ASO Chemistry
• 12.7 MEA Antisense Oligonucleotide (ASO) Therapeutics Market Size Estimation and Forecast by Route of Administration
• 12.8 GCC Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
• 12.9 South Africa Antisense Oligonucleotide (ASO) Therapeutics Market Analysis
• 12.10 Rest of MEA Antisense Oligonucleotide (ASO) Therapeutics Market Analysis

13 Company Profiles

• 13.1 Competitive Landscape, 2022
• 13.2 Strategic Outlook
• 13.3 Biogen
  • 13.3.1 Company Snapshot
  • 13.3.2 Company Overview
  • 13.3.3 Financial Analysis
    • 13.3.3.1 Net Revenue, 2017-2022
    • 13.3.3.2 Gross Profit, 2017-2022
    • 13.3.3.3 R&D, 2017-2022
  • 13.3.4 Product Benchmarking
  • 13.3.5 Strategic Outlook
• 13.4 Bio-Path Holdings
  • 13.4.1 Company Snapshot
  • 13.4.2 Company Overview
  • 13.4.3 Product Benchmarking
  • 13.4.4 Strategic Outlook
• 13.5 Ionis Pharmaceuticals, Inc.
  • 13.5.1 Company Snapshot
  • 13.5.2 Company Overview
  • 13.5.3 Financial Analysis
    • 13.5.3.1 Net Revenue, 2017-2022
    • 13.5.3.2 Gross Profit, 2017-2022
    • 13.5.3.3 R&D, 2017-2022
  • 13.5.4 Product Benchmarking
  • 13.5.5 Strategic Outlook
• 13.6 ProQR Therapeutics
  • 13.6.1 Company Snapshot
  • 13.6.2 Company Overview
  • 13.6.3 Product Benchmarking
  • 13.6.4 Strategic Outlook
• 13.7 Sarepta Therapeutics
  • 13.7.1 Company Snapshot
  • 13.7.2 Company Overview
  • 13.7.3 Financial Analysis
    • 13.7.3.1 Net Revenue, 2017-2022
    • 13.7.3.2 Gross Profit, 2017-2022
    • 13.7.3.3 R&D, 2017-2022
  • 13.7.4 Product Benchmarking
  • 13.7.5 Strategic Outlook
• 13.8 Alnylam Pharmaceuticals, Inc.
  • 13.8.1 Company Snapshot
  • 13.8.2 Company Overview
  • 13.8.3 Financial Analysis
    • 13.8.3.1 Net Revenue, 2017-2022
    • 13.8.3.2 Gross Profit, 2017-2022
    • 13.8.3.3 R&D, 2017-2022
  • 13.8.4 Product Benchmarking
  • 13.8.5 Strategic Outlook
• 13.9 Arrowhead Pharmaceuticals, Inc.
  • 13.9.1 Company Snapshot
  • 13.9.2 Company Overview
  • 13.9.3 Financial Analysis
    • 13.9.3.1 Net Revenue, 2017-2022
    • 13.9.3.2 Gross Profit, 2017-2022
    • 13.9.3.3 R&D, 2017-2022
  • 13.9.4 Product Benchmarking
  • 13.9.5 Strategic Outlook
• 13.10 GSK plc
  • 13.10.1 Company Snapshot
  • 13.10.2 Company Overview
  • 13.10.3 Financial Analysis
    • 13.10.3.1 Net Revenue, 2017-2022
    • 13.10.3.2 Gross Profit, 2017-2022
    • 13.10.3.3 R&D, 2017-2022
  • 13.10.4 Product Benchmarking
• 13.11 Geron Corporation (Geron)
  • 13.11.1 Company Snapshot
  • 13.11.2 Company Overview
  • 13.11.3 Financial Analysis
    • 13.11.3.1 Net Revenue, 2017-2022
    • 13.11.3.2 R&D, 2017-2022
  • 13.11.4 Product Benchmarking
• 13.12 Antisense Therapeutics Limited
  • 13.12.1 Company Snapshot
  • 13.12.2 Company Overview
  • 13.12.3 Financial Analysis
    • 13.12.3.1 Net Revenue, 2017-2022
    • 13.12.3.2 R&D, 2017-2022
  • 13.12.4 Product Benchmarking
  • 13.12.5 Strategic Outlook
• 13.13 Sterna Biologicals
  • 13.13.1 Company Snapshot
  • 13.13.2 Company Overview
  • 13.13.3 Product Benchmarking
• 13.14 Alector, Inc.
  • 13.14.1 Company Snapshot
  • 13.14.2 Company Overview
  • 13.14.3 Product Benchmarking
  • 13.14.4 Strategic Outlook
• 13.15 Dicerna Pharmaceuticals, Inc.
  • 13.15.1 Company Snapshot
  • 13.15.2 Company Overview
  • 13.15.3 Product Benchmarking
• 13.16 iCo Therapeutics Inc.
  • 13.16.1 Company Snapshot
  • 13.16.2 Company Overview
  • 13.16.3 Product Benchmarking
• 13.17 Roche Holding AG
  • 13.17.1 Company Snapshot
  • 13.17.2 Company Overview
  • 13.17.3 Financial Analysis
    • 13.17.3.1 Net Revenue, 2017-2022
    • 13.17.3.2 R&D, 2017-2022
  • 13.17.4 Product Benchmarking

14 Conclusion and Recommendations

• 14.1 Concluding Remarks from Visiongain
• 14.2 Recommendations for Market Players